Breye Therapeutics 🇩🇰
Copenhagen clinical-stage biotech developing oral therapies for retinal diseases
About Breye Therapeutics
Breye Therapeutics focuses on developing orally administered therapies aimed at treating retinal vascular diseases, specifically targeting conditions like diabetic retinopathy and age-related macular degeneration. The company employs innovative approaches to address significant unmet medical needs in ophthalmology, aiming for more effective treatments and improved patient outcomes.
Breye Therapeutics is a Denmark-based company founded in 2019, now around 11 people. It has raised $79.7M in disclosed funding. FundFinder classes it as Health & Bio.
Its investors also appear on FundFinder's most-active lists for Series A · Fintech (84 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A · €67.5M · Oct 2026
Novo Holdings- Novo Holdings — Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. · cheques £5M – £50M